According to the Institute for Safe Medication Practices (ISMP), the generic name for Strattera is at risk of being confused with:

Rationale

Atomoxetine

According to the Institute for Safe Medication Practices (ISMP), the generic name **atomoxetine** (for Strattera) is at risk of being confused with other medications due to its similar spelling and pronunciation. Such look-alike or sound-alike (LASA) errors can result in medication errors if prescriptions are misread or misinterpreted.

A (Atomoxetine) CORRECT

The generic name Atomoxetine is at risk of being confused with other medications due to its similar spelling and pronunciation.

B (dapagliflozin) YOUR ANSWER

This is incorrect. Dapagliflozin is a diabetes medication, and there is no documented LASA risk with atomoxetine.

C (rivaroxaban) YOUR ANSWER

This is incorrect. Rivaroxaban is an anticoagulant and is not known to be confused with atomoxetine.

D (famotidine) YOUR ANSWER

This is incorrect. Famotidine is an H2 receptor antagonist, with no documented confusion with atomoxetine.

Conclusion

The ISMP identifies atomoxetine as a medication at risk for LASA errors, emphasizing the need for careful verification when prescribing, dispensing, and administering Strattera to prevent potential medication errors.

According to the Institute for Safe Medication Practices (ISMP), the generic name for Strattera is at risk of being confused with:

Atomoxetine

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test